No Data
Sector Update: Health Care Stocks Softer in Friday Afternoon Trading
Health care stocks were easing Friday afternoon, with the NYSE Health Care Index down 0.2% and the Health Care Select Sector SPDR Fund (XLV) decreasing 0.1%. The iShares Biotechnology ETF (IBB) rose 0
CG Oncology Says Potential Combination Therapy for Bladder Cancer Meets Phase 2 Primary Endpoint
CG Oncology (CGON) said Friday that its phase 2 trial of cretostimogene plus pembrolizumab to treat BCG-unresponsive high-risk non-muscle invasive bladder cancer with carcinoma in situ met its primary
Express News | CG Oncology To Present Final Results From Phase 2 CORE-001 Study Of Cretostimogene Grenadenorepvec In Combination With Pembrolizumab In BCG-Unresponsive High-Risk NMIBC At ASCO 2024 Annual Meeting
Decoding 10 Analyst Evaluations For CG Oncology
In the latest quarter, 10 analysts provided ratings for CG Oncology (NASDAQ:CGON), showcasing a mix of bullish and bearish perspectives.The following table provides a quick overview of their recent ra
CG Oncology Price Target Raised to $50.00/Share From $43.00 by Goldman Sachs
CG Oncology Price Target Raised to $50.00/Share From $43.00 by Goldman Sachs
Goldman Sachs Upgrades CG Oncology to Buy From Neutral With $50 Price Target
CG Oncology (CGON) has an average outperform rating and a price target range of $50 to $86, according to analysts polled by Capital IQ.
The Real Wojak : Do you have like a top 3-5 that you like more than all the other ones? This list is way too long
72991267 : Glad I have some $Candel Therapeutics (CADL.US)$ after my disastrous SBFM.